Activation of coagulation and fibrinolysis during treatment with OKT3.
ten Berge
R J
RJ
Department of Internal Medicine, Academic Medical Centre, Amsterdam, The Netherlands.
Raasveld
M H
MH
van Diepen
F N
FN
Hack
C E
CE
D000990:Antithrombin III / Q000032:analysis; D003167:Complement Activation; D015926:Complement C3a / Q000032:analysis; D004797:Enzyme-Linked Immunosorbent Assay; D005342:Fibrinolysis; D006084:Graft Rejection / Q000628:therapy*; D006801:Humans; D016030:Kidney Transplantation / Q000276:immunology* / Q000502:physiology; D016853:Muromonab-CD3 / Q000627:therapeutic use*; D010447:Peptide Hydrolases / Q000032:analysis; D011863:Radioimmunoassay; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis / Q000378:metabolism*
D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; C046193:antithrombin III-protease complex; D015926:Complement C3a; D000990:Antithrombin III; D010447:Peptide Hydrolases; D010959:Tissue Plasminogen Activator